Loading...

We've got a brand new version of Simply Wall St! Try it out

TerrAscend

CNSX:TER
Snowflake Description

Imperfect balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
TER
CNSX
CA$976M
Imp Market Cap
  1. Home
  2. CA
  3. Pharmaceuticals & Biotech
Company description

TerrAscend Corp. engages in the cultivation and sale of medical and adult use cannabis in Canada. The last earnings update was 31 days ago. More info.


Add to Portfolio Compare Print
TER Share Price and Events
7 Day Returns
-0.5%
CNSX:TER
-5.9%
CA Pharmaceuticals
1.3%
CA Market
1 Year Returns
16.7%
CNSX:TER
-46.7%
CA Pharmaceuticals
-0.1%
CA Market
TER Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
TerrAscend (TER) -0.5% -5.4% -4.6% 16.7% - -
CA Pharmaceuticals -5.9% -3.4% -24.8% -46.7% 217.3% 286.4%
CA Market 1.3% 4.2% 1.6% -0.1% 8.4% 5.7%
1 Year Return vs Industry and Market
  • TER outperformed the Pharmaceuticals industry which returned -46.7% over the past year.
  • TER outperformed the Market in Canada which returned -0.1% over the past year.
Price Volatility
TER
Industry
5yr Volatility vs Market

TER Value

 Is TerrAscend undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for TerrAscend. This is due to cash flow or dividend data being unavailable. The share price is CA$6.01.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for TerrAscend's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are TerrAscend's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
CNSX:TER PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-06-30) in CAD CA$-0.47
CNSX:TER Share Price ** CNSX (2019-09-20) in CAD CA$6.01
Canada Pharmaceuticals Industry PE Ratio Median Figure of 13 Publicly-Listed Pharmaceuticals Companies 15.3x
Canada Market PE Ratio Median Figure of 539 Publicly-Listed Companies 14.14x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of TerrAscend.

CNSX:TER PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= CNSX:TER Share Price ÷ EPS (both in CAD)

= 6.01 ÷ -0.47

-12.82x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • TerrAscend is loss making, we can't compare its value to the CA Pharmaceuticals industry average.
  • TerrAscend is loss making, we can't compare the value of its earnings to the Canada market.
Price based on expected Growth
Does TerrAscend's expected growth come at a high price?
Raw Data
CNSX:TER PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -12.82x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Canada Pharmaceuticals Industry PEG Ratio Median Figure of 7 Publicly-Listed Pharmaceuticals Companies 1.56x
Canada Market PEG Ratio Median Figure of 245 Publicly-Listed Companies 1.02x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for TerrAscend, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on TerrAscend's assets?
Raw Data
CNSX:TER PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-06-30) in CAD CA$1.57
CNSX:TER Share Price * CNSX (2019-09-20) in CAD CA$6.01
Canada Pharmaceuticals Industry PB Ratio Median Figure of 151 Publicly-Listed Pharmaceuticals Companies 2.36x
Canada Market PB Ratio Median Figure of 2,457 Publicly-Listed Companies 1.43x
CNSX:TER PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= CNSX:TER Share Price ÷ Book Value per Share (both in CAD)

= 6.01 ÷ 1.57

3.83x

* Primary Listing of TerrAscend.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • TerrAscend is overvalued based on assets compared to the CA Pharmaceuticals industry average.
X
Value checks
We assess TerrAscend's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. TerrAscend has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

TER Future Performance

 How is TerrAscend expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as TerrAscend has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
97.7%
Expected Pharmaceuticals industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is TerrAscend expected to grow at an attractive rate?
  • Unable to compare TerrAscend's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare TerrAscend's earnings growth to the Canada market average as no estimate data is available.
  • Unable to compare TerrAscend's revenue growth to the Canada market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
CNSX:TER Future Growth Rates Data Sources
Data Point Source Value (per year)
Canada Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 97.7%
Canada Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 56.5%
Canada Market Earnings Growth Rate Market Cap Weighted Average 12.6%
Canada Market Revenue Growth Rate Market Cap Weighted Average 5.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
CNSX:TER Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in CAD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
CNSX:TER Future Estimates Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
CNSX:TER Past Financials Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income *
2019-06-30 39 -43 -44
2019-03-31 21 -35 -30
2018-12-31 7 -25 -22
2018-09-30 2 -27 -11
2018-06-30 0 -22 -10
2018-03-31 -7 -8
2017-12-31 -4 -7
2017-09-30 -4 -6
2017-06-30 0 -5
2017-03-31 -1 -1
2016-12-31 0 -1

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if TerrAscend is high growth as no earnings estimate data is available.
  • Unable to determine if TerrAscend is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
CNSX:TER Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from TerrAscend Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:TER Future Estimates Data
Date (Data in CAD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
CNSX:TER Past Financials Data
Date (Data in CAD Millions) EPS *
2019-06-30 -0.47
2019-03-31 -0.39
2018-12-31 -0.29
2018-09-30 -0.13
2018-06-30 -0.14
2018-03-31 -0.16
2017-12-31 -0.19
2017-09-30 -0.25
2017-06-30 -0.25
2017-03-31 -0.10
2016-12-31 -0.09

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if TerrAscend will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Take a look at our analysis of TER’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. TerrAscend's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. TerrAscend's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess TerrAscend's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Canada market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Canada market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
TerrAscend has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

TER Past Performance

  How has TerrAscend performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare TerrAscend's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • TerrAscend does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare TerrAscend's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare TerrAscend's 1-year growth to the CA Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
TerrAscend's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from TerrAscend Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:TER Past Revenue, Cash Flow and Net Income Data
Date (Data in CAD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-06-30 38.97 -44.31 45.12 0.41
2019-03-31 21.41 -30.37 32.66 0.27
2018-12-31 6.83 -22.03 24.46 0.14
2018-09-30 1.80 -11.08 15.16 0.10
2018-06-30 0.01 -10.08 9.50 0.03
2018-03-31 -8.43 8.25
2017-12-31 -6.81 6.12
2017-09-30 -6.43 5.36
2017-06-30 -4.83 4.07
2017-03-31 -1.44 1.12
2016-12-31 -0.87 0.87
2015-12-31 -0.76 0.75
2014-12-31 -0.40 0.40

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if TerrAscend has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if TerrAscend has efficiently used its assets last year compared to the CA Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if TerrAscend improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess TerrAscend's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
TerrAscend has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

TER Health

 How is TerrAscend's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up TerrAscend's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • TerrAscend's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • TerrAscend's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of TerrAscend's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 1.4x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from TerrAscend Company Filings, last reported 2 months ago.

CNSX:TER Past Debt and Equity Data
Date (Data in CAD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-06-30 151.54 50.50 22.29
2019-03-31 56.74 44.97 10.92
2018-12-31 57.90 12.68 29.46
2018-09-30 65.36 0.00 22.70
2018-06-30 64.30 0.00 28.62
2018-03-31 66.69 0.00 45.68
2017-12-31 67.37 0.00 51.82
2017-09-30 15.92 0.00 1.07
2017-06-30 3.40 9.72 1.53
2017-03-31 4.17 9.14 2.83
2016-12-31 2.08 0.00 3.33
2015-12-31 -0.57 0.00 0.10
2014-12-31 -0.34 0.00 0.06
  • TerrAscend's level of debt (33.3%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if TerrAscend's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • TerrAscend has less than a year of cash runway based on current free cash flow.
  • TerrAscend has less than a year of cash runway if free cash flow continues to grow at historical rates of 85.9% each year.
X
Financial health checks
We assess TerrAscend's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. TerrAscend has a total score of 2/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

TER Dividends

 What is TerrAscend's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from TerrAscend dividends.
If you bought CA$2,000 of TerrAscend shares you are expected to receive CA$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate TerrAscend's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate TerrAscend's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
CNSX:TER Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
North America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 2.8%
Canada Market Average Dividend Yield Market Cap Weighted Average of 334 Stocks 3.5%
Canada Minimum Threshold Dividend Yield 10th Percentile 1.1%
Canada Bottom 25% Dividend Yield 25th Percentile 2%
Canada Top 25% Dividend Yield 75th Percentile 5.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

CNSX:TER Future Dividends Estimate Data
Date (Data in CA$) Dividend per Share (annual) Avg. No. Analysts

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as TerrAscend has not reported any payouts.
  • Unable to verify if TerrAscend's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of TerrAscend's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as TerrAscend has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess TerrAscend's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can TerrAscend afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. TerrAscend has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

TER Management

 What is the CEO of TerrAscend's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Michael Nashat
COMPENSATION CA$201,667
AGE 35
TENURE AS CEO 1.7 years
CEO Bio

Dr. Michael Nashat is Co-Owner of Star-Pharma Pan-America Inc. Dr. Nashat serves as the Chief Executive Officer, Co-Founder and Director at TerrAscend Corp. since June 2019 and also served as the Chief Executive Officer since January 22, 2018 until June 2019. He served as Chief Operating Officer of Solace Health Inc. Dr. Nashat is Co-Founder of TerrAscend Corp. and serves as its Chief Operating Officer and Executive Vice President since 2017 until June 2019. Dr. Nashat serves as Executive Director for OnPharm Independent Pharmacy Group, which represents the commercial interest of over 340 pharmacies. He served as President of TerrAscend Corp. since January 22, 2018 until November 29, 2018. He serves as the Co-chair of the Ontario pharmacy owners advisory council and was a former member of the Ontario Ministry of Health and Long Term Care's Pharmacy Council. Dr. Nashat has been a Director of TerrAscend Corp. since March 7,2017. He serves as a Director of Solace Health Inc. He is a former board member for the Ontario College of Pharmacists, Canadian Foundation for pharmacy and the Canadian Association of Chain Drug Stores. Dr. Nashat received his Doctor of Pharmacy from the Albany College of Pharmacy and Health Science and completed his Post-Doctoral Fellowship in Neuroscience Medical Strategy at Bristol Myers Squibb/Rutgers University in New Jersey, U.S.

CEO Compensation
  • Michael's compensation has increased whilst company is loss making.
  • Michael's remuneration is lower than average for companies of similar size in Canada.
Management Team Tenure

Average tenure of the TerrAscend management team in years:

1.1
Average Tenure
  • The average tenure for the TerrAscend management team is less than 2 years, this suggests a new team.
Management Team

Michael Nashat

TITLE
CEO, Co-Founder & Director
COMPENSATION
CA$202K
AGE
35
TENURE
1.7 yrs

Adam Kozak

TITLE
Chief Financial Officer
COMPENSATION
CA$200K
TENURE
1.1 yrs

Matt Johnson

TITLE
President
TENURE
0.8 yrs

Brian Feldman

TITLE
General Counsel
TENURE
0.4 yrs

Dawn Vanek-Mithra

TITLE
Director of Marketing
TENURE
1.3 yrs
Board of Directors Tenure

Average tenure and age of the TerrAscend board of directors in years:

1.6
Average Tenure
50.5
Average Age
  • The average tenure for the TerrAscend board of directors is less than 3 years, this suggests a new board.
Board of Directors

Jason Wild

TITLE
Chairman of the Board

Michael Nashat

TITLE
CEO, Co-Founder & Director
COMPENSATION
CA$202K
AGE
35
TENURE
2.5 yrs

Richard Mavrinac

TITLE
Director
AGE
66
TENURE
2.5 yrs

Craig Collard

TITLE
Independent Director
AGE
53
TENURE
0.8 yrs

Lisa Swartzman

TITLE
Director
AGE
48
TENURE
0.4 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CA$) Value (CA$)
20. Jun 19 Buy Adam Kozak Individual 20. Jun 19 20. Jun 19 1,000 CA$6.10 CA$6,100
31. May 19 Buy Michael Nashat Individual 28. May 19 28. May 19 6,500 CA$7.64 CA$49,660
28. May 19 Buy Jason Wild Individual 27. May 19 27. May 19 35,157 CA$7.64 CA$268,599
28. May 19 Buy Insight Wellness Company 27. May 19 27. May 19 130,890 CA$7.64 CA$1,000,000
28. May 19 Buy Adam Kozak Individual 28. May 19 28. May 19 4,000 CA$7.64 CA$30,560
28. May 19 Buy JW Asset Management, LLC Company 27. May 19 27. May 19 3,069,500 CA$7.64 CA$23,450,982
21. May 19 Buy Brian Feldman Individual 15. May 19 15. May 19 8,816 CA$7.64 CA$67,354
21. May 19 Buy Matthew Johnson Individual 15. May 19 15. May 19 8,814 CA$7.64 CA$67,339
21. May 19 Buy Lisa Swartzman Individual 15. May 19 15. May 19 5,000 CA$7.64 CA$38,200
14. Dec 18 Sell Canopy Growth Corporation Company 30. Nov 18 30. Nov 18 -11,285,456 CA$1.10 CA$-12,414,000
13. Dec 18 Sell Canopy Rivers Inc. Company 30. Nov 18 30. Nov 18 -11,285,456 CA$1.10 CA$-10,500,000
13. Dec 18 Buy Canopy Rivers Inc. Company 30. Nov 18 30. Nov 18 9,545,456 CA$1.10 CA$10,500,000
X
Management checks
We assess TerrAscend's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. TerrAscend has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

TER News

Simply Wall St News

Need To Know: TerrAscend Corp. (CNSX:TER) Insiders Have Been Buying Shares

So we'll take a look at whether insiders have been buying or selling shares in TerrAscend Corp. … In the last twelve months TerrAscend insiders were buying shares, but not selling. … CNSX:TER Recent Insider Trading, September 4th 2019 Are TerrAscend Insiders Buying Or Selling?

Simply Wall St -

The TerrAscend Share Price Has Gained 154%, So Why Not Pay It Some Attention?

We'll need to follow TerrAscend for a while to get a better sense of its share price trend, since it hasn't been listed for particularly long. … TerrAscend isn't a profitable company, so it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). … When a company doesn't yet make profits, we'd generally expect to see good revenue growth.

Simply Wall St -

What Kind Of Shareholder Owns Most TerrAscend Corp (CNSX:TER) Stock?

A look at the shareholders of TerrAscend Corp (CNSX:TER) can tell us which group is most powerful. … So it's nice to see some insider ownership, because it may suggest that management is owner-oriented. … Taking a look at the our data on the ownership groups (below), it's seems that.

Simply Wall St -

Who Really Owns TerrAscend Corp (CNSX:TER)?

In this analysis, my focus will be on developing a perspective on TerrAscend Corp’s (CNSX:TER) latest ownership structure, a less discussed, but important factor. … The impact of a company's ownership structure affects both its short- and long-term performance. … The effect of an active institutional investor with a similar ownership as a passive pension-fund can be vastly different on a company's corporate governance and accountability to shareholders.

Simply Wall St -

TER Company Info

Description

TerrAscend Corp. engages in the cultivation and sale of medical and adult use cannabis in Canada. The company offers its cannabis products under the Knüba Naturals brand. It also provides education and support programs to physicians and patients through health care professionals. The company was incorporated in 2017 and is headquartered in Mississauga, Canada.

Details
Name: TerrAscend Corp.
TER
Exchange: CNSX
Founded: 2017
CA$976,200,057
CA$742,467,731
162,429,294
Website: http://www.terrascend.com
Address: TerrAscend Corp.
3610 Mavis Road,
Mississauga,
Ontario, L5C 1W2,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
CNSX TER New Common Shares Canadian National Stock Exchange CA CAD 03. May 2017
OTCPK TRSS.F New Common Shares Pink Sheets LLC US CAD 03. May 2017
DB TED New Common Shares Deutsche Boerse AG DE EUR 03. May 2017
Number of employees
Current staff
Staff numbers
101
TerrAscend employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/09/22 00:50
End of day share price update: 2019/09/20 00:00
Last estimates confirmation: 2019/04/24
Last earnings filing: 2019/08/22
Last earnings reported: 2019/06/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.